170 related articles for article (PubMed ID: 20832308)
21. A critical smn threshold in mice dictates onset of an intermediate spinal muscular atrophy phenotype associated with a distinct neuromuscular junction pathology.
Bowerman M; Murray LM; Beauvais A; Pinheiro B; Kothary R
Neuromuscul Disord; 2012 Mar; 22(3):263-76. PubMed ID: 22071333
[TBL] [Abstract][Full Text] [Related]
22. Somatic Therapy of a Mouse SMA Model with a U7 snRNA Gene Correcting SMN2 Splicing.
Odermatt P; Trüb J; Furrer L; Fricker R; Marti A; Schümperli D
Mol Ther; 2016 Oct; 24(10):1797-1805. PubMed ID: 27456062
[TBL] [Abstract][Full Text] [Related]
23. Defects in neuromuscular junction remodelling in the Smn(2B/-) mouse model of spinal muscular atrophy.
Murray LM; Beauvais A; Bhanot K; Kothary R
Neurobiol Dis; 2013 Jan; 49():57-67. PubMed ID: 22960106
[TBL] [Abstract][Full Text] [Related]
24. At the "junction" of spinal muscular atrophy pathogenesis: the role of neuromuscular junction dysfunction in SMA disease progression.
Goulet BB; Kothary R; Parks RJ
Curr Mol Med; 2013 Aug; 13(7):1160-74. PubMed ID: 23514457
[TBL] [Abstract][Full Text] [Related]
25. Therapeutics development for spinal muscular atrophy.
Sumner CJ
NeuroRx; 2006 Apr; 3(2):235-45. PubMed ID: 16554261
[TBL] [Abstract][Full Text] [Related]
26. 5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells.
Yuo CY; Lin HH; Chang YS; Yang WK; Chang JG
Ann Neurol; 2008 Jan; 63(1):26-34. PubMed ID: 17924536
[TBL] [Abstract][Full Text] [Related]
27. Cross-disease comparison of amyotrophic lateral sclerosis and spinal muscular atrophy reveals conservation of selective vulnerability but differential neuromuscular junction pathology.
Comley LH; Nijssen J; Frost-Nylen J; Hedlund E
J Comp Neurol; 2016 May; 524(7):1424-42. PubMed ID: 26502195
[TBL] [Abstract][Full Text] [Related]
28. Morpholino-Mediated Exon Inclusion for SMA.
Zhou H; Muntoni F
Methods Mol Biol; 2018; 1828():467-477. PubMed ID: 30171560
[TBL] [Abstract][Full Text] [Related]
29. Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy.
Kariya S; Park GH; Maeno-Hikichi Y; Leykekhman O; Lutz C; Arkovitz MS; Landmesser LT; Monani UR
Hum Mol Genet; 2008 Aug; 17(16):2552-69. PubMed ID: 18492800
[TBL] [Abstract][Full Text] [Related]
30. A transgene carrying an A2G missense mutation in the SMN gene modulates phenotypic severity in mice with severe (type I) spinal muscular atrophy.
Monani UR; Pastore MT; Gavrilina TO; Jablonka S; Le TT; Andreassi C; DiCocco JM; Lorson C; Androphy EJ; Sendtner M; Podell M; Burghes AH
J Cell Biol; 2003 Jan; 160(1):41-52. PubMed ID: 12515823
[TBL] [Abstract][Full Text] [Related]
31. Activation of Muscle-Specific Kinase (MuSK) Reduces Neuromuscular Defects in the Delta7 Mouse Model of Spinal Muscular Atrophy (SMA).
Feng Z; Lam S; Tenn ES; Ghosh AS; Cantor S; Zhang W; Yen PF; Chen KS; Burden S; Paushkin S; Ayalon G; Ko CP
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360794
[TBL] [Abstract][Full Text] [Related]
32. Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy.
Murray LM; Comley LH; Thomson D; Parkinson N; Talbot K; Gillingwater TH
Hum Mol Genet; 2008 Apr; 17(7):949-62. PubMed ID: 18065780
[TBL] [Abstract][Full Text] [Related]
33. Non-aggregating tau phosphorylation by cyclin-dependent kinase 5 contributes to motor neuron degeneration in spinal muscular atrophy.
Miller N; Feng Z; Edens BM; Yang B; Shi H; Sze CC; Hong BT; Su SC; Cantu JA; Topczewski J; Crawford TO; Ko CP; Sumner CJ; Ma L; Ma YC
J Neurosci; 2015 Apr; 35(15):6038-50. PubMed ID: 25878277
[TBL] [Abstract][Full Text] [Related]
34. Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice.
Kong L; Wang X; Choe DW; Polley M; Burnett BG; Bosch-Marcé M; Griffin JW; Rich MM; Sumner CJ
J Neurosci; 2009 Jan; 29(3):842-51. PubMed ID: 19158308
[TBL] [Abstract][Full Text] [Related]
35. Nerve sprouting capacity in a pharmacologically induced mouse model of spinal muscular atrophy.
Rimer M; Seaberg BL; Yen PF; Lam S; Hastings RL; Lee YI; Thompson WJ; Feng Z; Metzger F; Paushkin S; Ko CP
Sci Rep; 2019 May; 9(1):7799. PubMed ID: 31127156
[TBL] [Abstract][Full Text] [Related]
36. Pathologic Alterations in the Proteome of Synaptosomes from a Mouse Model of Spinal Muscular Atrophy.
Eshraghi M; Gombar R; De Repentigny Y; Vacratsis PO; Kothary R
J Proteome Res; 2019 Aug; 18(8):3042-3051. PubMed ID: 31262178
[TBL] [Abstract][Full Text] [Related]
37. Pre-symptomatic development of lower motor neuron connectivity in a mouse model of severe spinal muscular atrophy.
Murray LM; Lee S; Bäumer D; Parson SH; Talbot K; Gillingwater TH
Hum Mol Genet; 2010 Feb; 19(3):420-33. PubMed ID: 19884170
[TBL] [Abstract][Full Text] [Related]
38. Restoration of SMN in Schwann cells reverses myelination defects and improves neuromuscular function in spinal muscular atrophy.
Hunter G; Powis RA; Jones RA; Groen EJ; Shorrock HK; Lane FM; Zheng Y; Sherman DL; Brophy PJ; Gillingwater TH
Hum Mol Genet; 2016 Jul; 25(13):2853-2861. PubMed ID: 27170316
[TBL] [Abstract][Full Text] [Related]
39. Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells.
Grzeschik SM; Ganta M; Prior TW; Heavlin WD; Wang CH
Ann Neurol; 2005 Aug; 58(2):194-202. PubMed ID: 16049920
[TBL] [Abstract][Full Text] [Related]
40. Abnormal mitochondrial transport and morphology as early pathological changes in human models of spinal muscular atrophy.
Xu CC; Denton KR; Wang ZB; Zhang X; Li XJ
Dis Model Mech; 2016 Jan; 9(1):39-49. PubMed ID: 26586529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
